

# **PRIOR AUTHORIZATION REQUEST**

### <u>Rukobia</u>

| Patient Information:  |  |  |  |
|---|--|--|--|
| Name:   |  |  |  |
| Member ID:  |  |  |  |
| Address:  |  |  |  |
| City, State, Zip:   |  |  |  |
| Date of Birth:  |  |  |  |
|   |  |  |  |
| Prescriber Information:   |  |  |  |
| Name:   |  |  |  |
| NPI:  |  |  |  |
| Phone Number:   |  |  |  |
| Fax Number  |  |  |  |
| Address:  |  |  |  |
| City, State, Zip:   |  |  |  |
| Paguastad Madication  |  |  |  |
| Requested Medication  Rx Name:  |  |  |  |
| Rx Strength   |  |  |  |
| Rx Quantity:  |  |  |  |
| Rx Frequency:   |  |  |  |
| Rx Route of   |  |  |  |
| Administration:   |  |  |  |
| Diagnosis and ICD Code:   |  |  |  |
| prescribed a medication for your quantities can be provided. Plea Upon receipt of the completed SECTION A: Please no requests. Pharmacy primedications that are not | efit requires that we review certain requests for coverage with the per patient that requires Prior Authorization before benefit coverage or consists complete the following questions then fax this form to the toll-free of form, prescription benefit coverage will be determined based of the that supporting clinical documentation is required or authorization reviews can be subject to trial with the trial within the criteria. The policies are subject to trial with the criteria and updates to treatment quickles. | overage of a<br>number liste<br>on the plar<br>d for <b>AL</b><br>addition<br>o change | additional<br>ed below.<br>n's rules.<br>LPA<br>al |
| 1 Is the patient 18 ye<br>[If no, no further que  | ars of age or older?<br>estions.]  | Yes  | No   |
| •   | edication prescribed by or in consultation with a physician who reatment of HIV infection? estions.]   | Yes  | No   |
| What is the diagnos   | sis or indication?<br>infection (If checked, go to 4)  |  |  |

If you have any questions, call: 1-888-258-8250

Version 07.2025

# **PRIOR AUTHORIZATION REQUEST**

|   | [] Other (If checked, no further questions)   |     |    |
|---|---|-----|----|
| 4 | Is this request for initial therapy or for a continuation of therapy? [] Initial (If checked, go to 5)  |     |    |
|   | [] Continuation (If checked, go to 9)   |     |    |
| 5 | Is the patient failing a current antiretroviral regimen for HIV? [If no, no further questions.]   | Yes | No |
| 6 | Has the patient exhausted at least FOUR of the following antiretroviral classes defined as elimination of all antiretrovirals within a given class due to demonstrated or projected resistance to the agent(s) in that class: (a) Nucleoside reverse transcriptase inhibitor (Examples include abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, tenofovir alafenamide, zidovudine); (b) Non-nucleoside reverse transcriptase inhibitor (Examples include delaviridine, efavirenz, etravirine, nevirapine, nevirapine XR, rilpivirine); (c) Protease inhibitor (Examples include atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, tipranavir); (d) Fusion inhibitor (Examples include Fuzeon [enfuviritide for injection]); (e) Integrase strand transfer inhibitors include raltegravir, dolutegravir, elvitegravir); (f) CCR5 antagonist (Examples include Selzentry [maraviroc tablets])? [If yes, skip to question 8.]        | Yes | No |
| 7 | Has the patient exhausted at least FOUR of the following antiretroviral classes defined as elimination of all antiretrovirals within a given class due to significant intolerance: (a) Nucleoside reverse transcriptase inhibitor (Examples include abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, tenofovir alafenamide, zidovudine); (b) Non-nucleoside reverse transcriptase inhibitor (Examples include delaviridine, efavirenz, etravirine, nevirapine, nevirapine XR, rilpivirine); (c) Protease inhibitor (Examples include atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, tipranavir); (d) Fusion inhibitor (Examples include Fuzeon [enfuviritide for injection]); (e) Integrase strand transfer inhibitor (Examples of integrase strand transfer inhibitors include raltegravir, dolutegravir, elvitegravir); (f) CCR5 antagonist (Examples include Selzentry [maraviroc tablets])? [If no, no further questions.] | Yes | No |
| 8 | Will the requested medication be taken in combination with an optimized antiviral background regimen including one or more other antiretroviral agents? [No further questions.]   | Yes | No |
| 9 | Will the requested medication continue to be taken in combination with an optimized antiviral background regimen including one or more other antiretroviral agents?   | Yes | No |

If you have any questions, call: 1-888-258-8250



#### PRIOR AUTHORIZATION REQUEST

[If no, no further questions.]

Has the patient responded to a Rukobia-containing regimen, as determined by the Yes No prescriber?

[Note: Examples of a response are HIV RNA less than 40 cells/mm3, HIV-1 RNA greater than or equal to 0.5 log10 reduction from baseline in viral load.]

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

### FAX COMPLETED FORM TO: 1-833-896-0656

**Disclaimer:** An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**Confidentiality:** The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250

Version 07.2025